Literature DB >> 9414429

Regression of C6 rat brain tumors by cells expressing an antisense insulin-like growth factor I receptor RNA.

M Resnicoff1, J Tjuvajev, H L Rotman, D Abraham, M Curtis, R Aiken, R Baserga.   

Abstract

We have previously shown that C6 cells expressing an antisense insulin-like growth factor I receptor (IGF-IR) RNA are no longer tumorigenic in syngeneic rats, protecting them from subsequent subcutaneous tumor challenge and causing regression of established subcutaneous tumors. In the present study, we have investigated the efficacy of this strategy on intracerebrally implanted C6 rat glioblastoma cells. We demonstrate that C6 cells expressing an antisense IGF-IR RNA implanted for 24 h in the subcutaneous tissue of the rats are able to elicit an anti-tumor response in the brain, leading to complete brain tumor regression and long-term survival of the rats. These findings suggest the possibility of therapeutic intervention in human gliomas.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9414429

Source DB:  PubMed          Journal:  J Exp Ther Oncol        ISSN: 1359-4117


  13 in total

1.  Antagonists of growth hormone-releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice.

Authors:  H Kiaris; A V Schally; J L Varga
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

2.  A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging.

Authors:  Vladimir Ponomarev; Michael Doubrovin; Inna Serganova; Jelena Vider; Aleksander Shavrin; Tatiana Beresten; Anna Ivanova; Ludmila Ageyeva; Vilia Tourkova; Julius Balatoni; William Bornmann; Ronald Blasberg; Juri Gelovani Tjuvajev
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-03-11       Impact factor: 9.236

Review 3.  Role of insulin-like growth factor-1R system in colorectal carcinogenesis.

Authors:  Erin A Donovan; Shivaani Kummar
Journal:  Crit Rev Oncol Hematol       Date:  2007-10-31       Impact factor: 6.312

Review 4.  The IGF/IGFBP system in CNS malignancy.

Authors:  W Zumkeller; M Westphal
Journal:  Mol Pathol       Date:  2001-08

5.  ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARalpha -mediated inhibition of glioma cell motility in vitro.

Authors:  Justyna Drukala; Katarzyna Urbanska; Anna Wilk; Maja Grabacka; Ewa Wybieralska; Luis Del Valle; Zbigniew Madeja; Krzysztof Reiss
Journal:  Mol Cancer       Date:  2010-06-22       Impact factor: 27.401

6.  An experimental study of dendritic cells-mediated immunotherapy against intracranial gliomas in rats.

Authors:  Xinmei Zhu; Chuanzhen Lu; Baoguo Xiao; Jian Qiao; Yi Sun
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

Review 7.  In vivo models of primary brain tumors: pitfalls and perspectives.

Authors:  Peter C Huszthy; Inderjit Daphu; Simone P Niclou; Daniel Stieber; Janice M Nigro; Per Ø Sakariassen; Hrvoje Miletic; Frits Thorsen; Rolf Bjerkvig
Journal:  Neuro Oncol       Date:  2012-06-07       Impact factor: 12.300

Review 8.  Role of insulin-like growth factor 1 receptor signalling in cancer.

Authors:  O Larsson; A Girnita; L Girnita
Journal:  Br J Cancer       Date:  2005-06-20       Impact factor: 7.640

9.  Role of receptor tyrosine kinases and their ligands in glioblastoma.

Authors:  Estefanía Carrasco-García; Miguel Saceda; Isabel Martínez-Lacaci
Journal:  Cells       Date:  2014-04-04       Impact factor: 6.600

10.  Identification of Clinical Relevant Molecular Subtypes of Pheochromocytoma.

Authors:  Umair Ali Khan Saddozai; Fengling Wang; Muhammad Usman Akbar; Lu Zhang; Yang An; Wan Zhu; Longxiang Xie; Yongqiang Li; Xinying Ji; Xiangqian Guo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-21       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.